Analysts: Buy Avon on Weakness and 3 More Research Notes to Consider
Avon Products (NYSE:AVP): After Avon reported higher-than-expected earnings per share, BMO Capital thinks the company’s turnaround remains on track, despite some headwinds. The firm suggests buying on any signs of weakness.
Cognizant (NASDAQ:CTSH): Oppenheimer believes that Cognizant’s fundamentals are healthy, and the firm expects the company to report second-quarter results that are at least in line with guidance. The firm thinks Cognizant could raise its full-year guidance for 2013 and has reiterated an Outperform rating on the stock.
Covidien (NYSE:COV): Susquehanna raised its price target on Covidien to $68 from $65 following solid third-quarter results. The firm cited revenue improvement and the potential for higher selling, general, and administrative expenses, as well as leverage and manufacturing consolidation. Shares are Positive rated by Susquehanna.
Apollo Group (NASDAQ:APOL): Wells Fargo says there is speculation an activist investor could look to invest in Apollo because of the potential monetization of its technology. However, the firm doesn’t think that other schools will be very interested in using Apollo’s technology. Furthermore, Apollo would undermine its own competitive advantage if it provided its technology to competitors, the firm said, and kept a Market Perform rating on the stock.
Don’t Miss: Facebook Wants to Take Over Your Phone.